CinA mediates multidrug tolerance in Mycobacterium tuberculosis.
- Additional Document Info
- View All
The ability of Mycobacterium tuberculosis (Mtb) to resist and tolerate antibiotics complicates the development of improved tuberculosis (TB) chemotherapies. Here we define the Mtb protein CinA as a major determinant of drug tolerance and as a potential target to shorten TB chemotherapy. By reducing the fraction of drug-tolerant persisters, genetic inactivation of cinA accelerated killing of Mtb by four antibiotics in clinical use: isoniazid, ethionamide, delamanid and pretomanid. Mtb cinA was killed rapidly in conditions known to impede the efficacy of isoniazid, such as during nutrient starvation, during persistence in a caseum mimetic, in activated macrophages and during chronic mouse infection. Deletion of CinA also increased in vivo killing of Mtb by BPaL, a combination of pretomanid, bedaquiline and linezolid that is used to treat highly drug-resistant TB. Genetic and drug metabolism studies suggest that CinA mediates drug tolerance via cleavage of NAD-drug adducts.
author list (cited authors)
Kreutzfeldt, K. M., Jansen, R. S., Hartman, T. E., Gouzy, A., Wang, R., Krieger, I. V., ... Ehrt, S.
complete list of authors
Kreutzfeldt, Kaj M||Jansen, Robert S||Hartman, Travis E||Gouzy, Alexandre||Wang, Ruojun||Krieger, Inna V||Zimmerman, Matthew D||Gengenbacher, Martin||Sarathy, Jansy P||Xie, Min||Dartois, Véronique||Sacchettini, James C||Rhee, Kyu Y||Schnappinger, Dirk||Ehrt, Sabine